FAI insert + Sham injection
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Infectious Uveitis
Conditions
Non-Infectious Uveitis
Trial Timeline
Aug 2, 2013 → Mar 26, 2018
NCT ID
NCT01694186About FAI insert + Sham injection
FAI insert + Sham injection is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Non-Infectious Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01694186. Target conditions include Non-Infectious Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01694186 | Phase 3 | Completed |
Competing Products
10 competing products in Non-Infectious Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Adalimumab | AbbVie | Approved | 85 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 72 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |